164 related articles for article (PubMed ID: 37846772)
1. Patterns of antiseizure medication utilization in the Human Epilepsy Project.
Fox J; Barnard S; Agashe SH; Holmes MG; Gidal B; Klein P; Abou-Khalil BW; French J;
Epilepsia; 2023 Dec; 64(12):3196-3204. PubMed ID: 37846772
[TBL] [Abstract][Full Text] [Related]
2. Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020.
Hochbaum M; Kienitz R; Rosenow F; Schulz J; Habermehl L; Langenbruch L; Kovac S; Knake S; von Podewils F; von Brauchitsch S; Hamacher M; Strzelczyk A; Willems LM
Epilepsy Behav; 2022 May; 130():108666. PubMed ID: 35339390
[TBL] [Abstract][Full Text] [Related]
3. Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Cohen JM; Alvestad S; Cesta CE; Bjørk MH; Leinonen MK; Nørgaard M; Einarsdóttir K; Engeland A; Gissler M; Karlstad Ø; Klungsøyr K; Odsbu I; Reutfors J; Selmer RM; Tomson T; Ulrichsen SP; Zoega H; Furu K
Ann Neurol; 2023 Mar; 93(3):551-562. PubMed ID: 36433783
[TBL] [Abstract][Full Text] [Related]
4. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011412. PubMed ID: 29243813
[TBL] [Abstract][Full Text] [Related]
5. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011412. PubMed ID: 28661008
[TBL] [Abstract][Full Text] [Related]
6. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.
Cerulli Irelli E; Cocchi E; Morano A; Gesche J; Caraballo RH; Lattanzi S; Strigaro G; Catania C; Ferlazzo E; Pascarella A; Casciato S; Quarato P; Pizzanelli C; Pulitano P; Giuliano L; Viola V; Mostacci B; Fortunato F; Marini C; Di Gennaro G; Gambardella A; Labate A; Operto FF; Giallonardo AT; Baykan B; Beier CP; Di Bonaventura C;
JAMA Neurol; 2023 Nov; 80(11):1174-1181. PubMed ID: 37782485
[TBL] [Abstract][Full Text] [Related]
7. Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy.
Larsson D; Baftiu A; Johannessen Landmark C; von Euler M; Kumlien E; Åsberg S; Zelano J
JAMA Neurol; 2022 Feb; 79(2):169-175. PubMed ID: 34902006
[TBL] [Abstract][Full Text] [Related]
8. Second antiseizure medication monotherapy in patients with adult-onset epilepsy: A register-based analysis.
Polychronidis K; Håkansson S; Hosseini Ashtiani S; Idegård A; Larsson D; Zelano J
Epilepsy Behav; 2024 Jun; 155():109792. PubMed ID: 38669974
[TBL] [Abstract][Full Text] [Related]
9. Trends in antiseizure medications utilization among women of childbearing age with epilepsy in Poland between 2015 and 2019.
Wójcik K; Franciszek Kołek M; Dec-Ćwiek M; Słowik A; Bosak M
Epilepsy Behav; 2023 Feb; 139():109091. PubMed ID: 36682232
[TBL] [Abstract][Full Text] [Related]
10. Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Yu L; Feng J; Yu Z; Dai H
Epilepsy Res; 2020 Nov; 167():106448. PubMed ID: 32916644
[TBL] [Abstract][Full Text] [Related]
11. Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020.
Håkansson S; Wickström R; Zelano J
Pediatr Neurol; 2023 Jul; 144():19-25. PubMed ID: 37116405
[TBL] [Abstract][Full Text] [Related]
12. Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.
Battino D; Tomson T; Bonizzoni E; Craig J; Perucca E; Sabers A; Thomas S; Alvestad S; Perucca P; Vajda F;
JAMA Neurol; 2024 May; 81(5):481-489. PubMed ID: 38497990
[TBL] [Abstract][Full Text] [Related]
13. Trends in Antiseizure Medication Initiation, Switch, or Termination in Patients With Newly Diagnosed Epilepsy: A Nationwide Study.
Bolin K; Patric B; Tomson T
Neurology; 2024 Jul; 103(2):e209500. PubMed ID: 38870473
[TBL] [Abstract][Full Text] [Related]
14. Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy.
Terman SW; Youngerman BE; Choi H; Burke JF
Epilepsia; 2022 Jun; 63(6):1571-1579. PubMed ID: 35294775
[TBL] [Abstract][Full Text] [Related]
15. Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Dreier JW; Bjørk MH; Alvestad S; Gissler M; Igland J; Leinonen MK; Sun Y; Zoega H; Cohen JM; Furu K; Tomson T; Christensen J
JAMA Neurol; 2023 Jun; 80(6):568-577. PubMed ID: 37067807
[TBL] [Abstract][Full Text] [Related]
16. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
17. Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Bjørk MH; Zoega H; Leinonen MK; Cohen JM; Dreier JW; Furu K; Gilhus NE; Gissler M; Hálfdánarson Ó; Igland J; Sun Y; Tomson T; Alvestad S; Christensen J
JAMA Neurol; 2022 Jul; 79(7):672-681. PubMed ID: 35639399
[TBL] [Abstract][Full Text] [Related]
18. Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure.
Fairclough S; Goodden J; Chumas P; Mathew R; Maguire M
Epilepsia; 2023 Apr; 64(4):857-865. PubMed ID: 36636895
[TBL] [Abstract][Full Text] [Related]
19. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Perucca E; Sabers A; Thomas SV; Vajda F;
Lancet Neurol; 2018 Jun; 17(6):530-538. PubMed ID: 29680205
[TBL] [Abstract][Full Text] [Related]
20. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
